Johnson & Johnson has added to the flurry of M&A deals in pharma with an agreement to buy US biotech Halda Therapeutics and its RIPTAC platform for generating small-molecule cancer drugs. J&J said it ...
On November 18, Johnson & Johnson (NYSE:JNJ) revealed that it plans to acquire privately held Halda Therapeutics for $3.05 billion in c ash, a move intended to strengthen its position in ...
Halda Therapeutics, a New Haven-based company developing cancer treatments, announced this week an agreement to be acquired for $3.05 billion by Johnson & Johnson - one of the largest deals involving ...
Johnson & Johnson will pay US$3.05 billion to acquire Halda Therapeutics and its portfolio of anticancer induced-proximity drugs. Halda’s heterobifunctional regulated induced proximity targeting ...
Johnson & Johnson (J&J) has announced that it will acquire Halda Therapeutics for approximately US$3.05 billion in cash. The acquisition brings Halda’s novel drug‐discovery platform and pipeline into ...
Halda Therapeutics researchers at work in the company’s lab. Johnson & Johnson has agreed to acquire Halda for $3.05 billion cash, the companies said today, in a deal designed to expand the buyer’s ...
Johnson & Johnson acquires Halda Therapeutics for $3 billion to strengthen its oncology portfolio, focusing on prostate cancer therapies. The acquisition includes HLD-0915, a clinical-stage therapy ...
[NEW YORK] Johnson & Johnson has agreed to buy the cancer treatment biotech Halda Therapeutics for US$3.05 billion cash, part of a strategy to cope with eroding sales for its major psoriasis drug.
Nov 17 (Reuters) - Johnson & Johnson (JNJ.N), opens new tab said on Monday it would buy privately held Halda Therapeutics for $3.05 billion in cash, aiming to expand its presence in treatments ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback